Loading clinical trials...
Loading clinical trials...
Anti-tnf Inhibitor Antibody-mediated Blockade Of Drug Efficacy In Rheumatoid Arthritis (Antibody-ra)
The purpose of this study is to examine the relationship between anti-drug antibodies, serum drug concentrations, and clinical response for rheumatoid arthritis patients being treated with etanercept, adalimumab or infliximab.
cross-sectional Population will be selected through convenience sampling. Patients sequentially visiting the rheumatology clinic for routine care who are receiving etanercept, adalimumab, or infliximab for between 6 and 24 months will be evaluated for eligibility and interest in participation. A maximum of 200 patients per treatment will be enrolled.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Arizona Arthritis & Rheumatology
Glendale, Arizona, United States
Arizona Arthritis & Rheumatology Associates, P. C.
Mesa, Arizona, United States
Arizona Arthritis & Rheumatology
Phoenix, Arizona, United States
Arizona Arthritis and Rheumatology Research, PLLC
Phoenix, Arizona, United States
Arizona Arthritis & Rheumatology Research
Sun City, Arizona, United States
Mercy Clinic Hot Springs Communities
Hot Springs, Arkansas, United States
Sutter Institute for Medical Research
Sacramento, California, United States
Arthritis Care Center, Incorporated
San Jose, California, United States
Rheumatology Consultants of Delaware dba Delaware Arthritis
Lewes, Delaware, United States
Omega Research Consultants, LLC
DeBary, Florida, United States
Start Date
January 1, 2014
Primary Completion Date
December 1, 2014
Completion Date
December 1, 2014
Last Updated
January 12, 2016
605
ACTUAL participants
no intervention
OTHER
no intervention
OTHER
no intervention
OTHER
Lead Sponsor
Pfizer
NCT06647069
NCT07484243
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions